Jámbor C, Bremerich D, Moritz A, Seifried E, Zwissler B
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt a.M.
Anaesthesist. 2008 Apr;57(4):374-81. doi: 10.1007/s00101-008-1336-8.
After cardiac surgery with extracorporeal circulation, approximately 20% of patients show significant bleeding tendencies and 5% require re-intervention. In 50% of patients undergoing re-operation, no surgical cause can be determined, suggesting coagulopathy after cardiopulmonary bypass (CPB). For perioperative management of transfusion of blood products and coagulation factor concentrates, a clinical algorithm for the perioperative hemostatic therapy in patients undergoing cardiac surgery with CPB has been developed. The currently available evidence and the point of care methods routinely accessible in our institution (blood gas analysis, ACT, point of care Quick value, aPTT and platelet count) were used. The intervention with plasma products, coagulation factor concentrates and hemostatic drugs after extracorporeal circulation are described. Extensive bleeding history as well as the efficacy and side effects of antifibrinolytic treatment are discussed.
在体外循环心脏手术后,约20%的患者出现明显的出血倾向,5%的患者需要再次干预。在接受再次手术的患者中,50%无法确定手术原因,提示体外循环(CPB)后发生凝血病。为了围手术期血液制品和凝血因子浓缩物的输血管理,已制定了CPB心脏手术患者围手术期止血治疗的临床算法。使用了当前可得的证据以及我们机构常规可用的床旁检测方法(血气分析、活化凝血时间、床旁快速值、活化部分凝血活酶时间和血小板计数)。描述了体外循环后使用血浆制品、凝血因子浓缩物和止血药物的干预措施。讨论了广泛的出血史以及抗纤溶治疗的疗效和副作用。